Retour
Prix Incyte Corp (INCY)
Graphique du cours de l'action INCY
INCY Gagner
Incyte Corp
$101.1
0.34%
$0.34
À la fermeture : Feb 13, 16:00:00 GMT-5
$100.06
-1.02%
$-1.03
Post-Marché: Feb 13, 17:57:45 GMT-5
Derniers résultats des bénéfices : Q4 '25
Signalé : 2026-02-10
Bénéfices historiques
Trimestriellement
Annuel
EPS
Revenus
Earnings FAQ
Comment le bénéfice par action récent de INCY se compare-t-il aux attentes ?
Comment les revenus de Incyte Corp INCY se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Incyte Corp ?
Quel est le score de qualité des bénéfices pour Incyte Corp ?
Quand Incyte Corp publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Incyte Corp ?
Incyte Corp a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$100.75
Prix d'ouverture
$101.47
Plage de la journée
$100.06 - $103.18
Plage de 52 semaines
$53.56 - $112.29
Volume
1.3M
Volume moyen
2.0M
BPA (TTM)
5.91
Rendement en dividend
--
Capitalisation boursière
$19.6B
Qu’est-ce que INCY ?
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.